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Abstract  
Objective. Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease leading 
to bile duct strictures and fibrosis, and predisposing to cholangiocarcinoma (CCA). Biliary 
dysplasia is a known precursor of CCA. In our unit PSC patients undergo regular 
surveillance with ERC and brush cytology (BC), and liver transplantation is an option in case 
with biliary dysplasia. We evaluated the risk factors for biliary dysplasia and CCA based on 
ERC imaging, BC and liver function tests. 
Patients and methods: 788 ERCs were performed with BC for 447 PSC patients. ERC 
images were evaluated using the modified Amsterdam score, neutrophilic inflammation was 
assessed in BC, and liver function tests were collected. Ploidy analysis with DNA flow 
cytometry was performed in cases with advanced PSC or previous suspicious 
BC/aneuploidy. The endpoint was either a benign disease course (follow-up for > 2.4 years 
after the latest ERC), benign histology, biliary dysplasia, or CCA.  
Results: Benign disease course was seen in 424/447 (including 23 cases with biliary 
dysplasia), and CCA in 17 (3.8%) patients. Gallbladder carcinoma/carcinoma in situ was 
diagnosed in 3 patients. Advanced ERC findings, male gender, suspicious BC, aneuploidy 
in flow cytometry, inflammation, and elevation of ALP, bilirubin, ALT, AST, GGT, CEA, and 
CA19-9 represented significant risk factors for CCA in univariate analysis.  
Conclusions: PSC patients with advanced bile duct disease and elevated liver enzymes, 
CEA or CA19-9, inflammation or suspicious BC are most likely to develop CCA. These 
patients may benefit from surveillance with BC if early liver transplantation is possible.  
Keywords: biliary dysplasia; cholangiocarcinoma; liver transplantation 
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; BC, brush cytology; CA19-9, carbohydrate antigen 19-9; CCA, 
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cholangiocarcinoma; CEA, carcinoembryonic antigen; ERC, endoscopic retrograde 
cholangiography; GGT, gamma-glutamyl transferase; HR, hazard ratio; IBD, inflammatory 
bowel disease; LT, liver transplantation; mERC score, modified Amsterdam ERC score; 
PSC, primary sclerosing cholangitis; UDCA, ursodeoxycholic acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
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Primary sclerosing cholangitis (PSC) is a chronic progressive disease leading to strictures 
of the bile ducts and, eventually, cirrhosis. PSC patients carry a markedly increased risk for 
cholangiocarcinoma (CCA), with the lifetime risk reaching nearly 10% (1), or 398-fold 
compared with the general population (2). CCA represents a common cause of death among 
PSC patients, whereby half of all CCAs are detected within one year of a PSC diagnosis 
(3,4), depending on the indications for first endoscopic retrograde cholangiography (ERC) 
and magnetic resonance imaging. Several risk factors for CCA in PSC patients have been 
identified, such as a long history of inflammatory bowel disease (IBD), hyperbilirubinemia, 
and an older age at PSC diagnosis (2,5). Like many other carcinomas, CCA is thought to 
develop through metaplasia, low-grade dysplasia, and high-grade dysplasia (6). CCA 
generally presents as a contraindication for liver transplantation (LT) and carries a dismal 
prognosis.  
The diagnosis of early CCA is difficult with currently available methods. At present, no 
recommendations exist for the screening of PSC patients for biliary neoplasia without 
dominant strictures (7). In some centres, such as in our hospital, early LT to prevent 
dysplasia progression to CCA is an option if biliary dysplasia is repeatedly documented in 
brush cytology (BC) (8,9). Only 30% of US transplantation centres screen for hepatobiliary 
malignancy with BC prior to LT (10), even among listed patients. BC possibly combined with 
other techniques is used to diagnose cytological dysplasia or CCA among PSC patients (8). 
BC is quite specific but its sensitivity is rather low (11). Inflammation of the bile ducts is 
thought to predispose for CCA (12). Inflammation may also induce atypia in the biliary 
epithelium, making BC interpretation challenging. Polysomy with fluorescence in situ 
hybridisation (13) or aneuploidy with DNA flow cytometry (9,14) appear to increase the 
sensitivity and specificity for detecting biliary neoplasia. Most CCAs among PSC patients 
are located in the extrahepatic or perihilar bile ducts remaining reachable with BC (4).  
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In our earlier study, we found that even in a mostly asymptomatic PSC population, advanced 
extrahepatic ERC changes and elevated aminotransferases during the diagnostic ERC 
represented significant risk factors for biliary neoplasia (15). 
This study aimed to find patients at highest risk for CCA by using regular systematic 
surveillance with ERC with BC in a non-selected group of PSC patients, and to identify the 
risk factors associated with the development of CCA and dysplasia using detailed ERC 
scoring, BC, and laboratory findings. 
 
Patients and methods 
This large, single-centre study in a population of PSC patients took place at Helsinki 
University Hospital, where ERC with BC were performed during the study period. Since 
2006, PSC patients in our hospital regularly underwent ERC with BC, in addition to 
laboratory testing and imaging. The frequency of ERC depends on both the severity of the 
PSC (defined by ERC changes) and the previous BC findings (Figure 1). 
Patients. We collected patient data from the Department of Pathology, Meilahti Laboratories, 
Helsinki University Hospital and the PSC registry of the Clinic of Gastroenterology, Helsinki 
University Hospital. We included PSC patients over 18 years undergoing ERC and BC 
surveillance between 1 January 2006 and 31 December 2011 in our study. In total, our 
sample included 460 PSC patients. Thirteen patients were excluded from the study due to 
loss of follow up (moved elsewhere or noncompliance). We also excluded patients with 
secondary sclerosing cholangitis and immunoglobulin G4 related cholangitis.  Table I shows 
the patient characteristics. More than half of all patients (247 or 55%) were male. In our 
sample, 185 patients were diagnosed with PSC earlier than 2006 or elsewhere after 2006 
and subsequently monitored in our unit (earlier cohort), and 262 were diagnosed with PSC 
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in our unit between 2006 and 2011 (surveillance cohort). In total, 788 ERCs were performed 
(1–6 ERCs/patient). In 137 patients, only one ERC was performed, and among twenty-one 
of them it was due to reached endpoint (six CCAs, fifteen liver transplantations), rest of them 
not yet having the second ERC during surveillance time. In majority of the patients (n=310), 
2-6 ERCs were performed. ERCs were planned according to the surveillance protocol (Fig. 
1). The median time between the first and the second ERC was 2.2 years, and thereafter 
1.1 years. In 93% of the cases, the main indication for ERC was either verification of PSC 
diagnosis or surveillance according to protocol. In 6%, the indication was evaluation for liver 
transplantation, and in 1%, treating a stricture. However, strictures were treated with 
dilatation mostly during normal surveillance ERCs as indicated. The median age at the time 
of PSC diagnosis was 36 years. Most patients (74%) presented with concomitant IBD, most 
commonly ulcerative colitis. We retrieved the presence of possible symptoms of liver 
disease (abdominal pain, jaundice, pruritus, cholangitis, fever, and fatigue) from patient 
charts. Only 18% of patients were symptomatic in the beginning of surveillance. We also 
registered the data on the use of ursodeoxycholic acid (UDCA).  
ERCs. ERCs were performed by two experienced gastroenterologists (MF and KJ) using 
the balloon occlusion technique to ensure adequate and standardised filling of intra- and 
extrahepatic bile ducts in successive ERCs. Images were evaluated using the modified 
Amsterdam score (mERC score) (15). BC was collected systematically in every patient from 
extra- and intrahepatic bile ducts, with the aim of reaching as many intrahepatic branches 
as possible, regardless of the presence or absence of dominant strictures, in order to collect 
a substantial number of cells for evaluation as described elsewhere (9).  
Brush cytology. BCs were processed and evaluated as described earlier (9). We performed 
cytological evaluation from cytospin and cell-block slides using three-tiered criteria as 
benign, suspicious, or malignant (corresponding CCA). Suspicious cytology included any of 
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the following features: biphasic cell population, lack of polarity, nuclear moulding, nuclear 
membrane irregularities, high nuclear-cytoplasm ratio, hyper/hypochromacy, and lack of 
cohesion. Neutrophilic inflammation in BC was evaluated semi-quantitatively 
(0=neutrophils/epithelial cells <0.05, 1=neutrophils/epithelial cells 0.05–0.4, and 
2=neutrophils/epithelial cells >0.4). If the number of epithelial cells was low (below 200), we 
assumed that inflammation was absent.  
DNA ploidity. In cases with advanced PSC or with a previous suspicious cytology or 
aneuploidy, we also collected a sample for DNA ploidy analysis. In these cases, a separate 
brush sample for DNA flow cytometry was collected and processed as previously reported 
(9). In this study, we considered a DNA index over 1.1 as aneuploid to avoid false-positive 
results. 
Histology. Two pathologists (JA and SB) blinded to the original findings re-evaluated 
explanted livers. Bile ducts were graded as benign (including regenerative/inflammatory 
atypia), dysplastic (two-tiered evaluation to low-grade and high-grade; carcinoma in situ 
included in high-grade dysplasia), or invasive CCA. For patients with CCA and no LT, CCA 
was verified from histology, either from a surgical specimen or a core needle biopsy, or 
malignant BC with the imaging results consistent with CCA. Gallbladder carcinomas were 
verified from surgical specimens. 
Laboratory values. Routine laboratory tests were taken the day before ERC using the 
appropriate methods. Results at the beginning of surveillance are presented in Table II.  
Endpoints. The endpoints in the primary analyses of this study included 1) CCA, or 2) non-
malignant disease course with benign biliary histology or biliary dysplasia in an explanted 
liver or benign follow-up for at least 2.4 years following the last ERC. The status of patients 
with benign follow-up was monitored until 31 May 2014, and, for patients with LT or CCA, 
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until LT was performed or CCA detected. Gallbladder carcinomas were only reported and 
not used as the endpoint, because the BC findings most likely did not provide information 
about gallbladder epithelium.  
Statistics. Statistical analyses were performed using IBM SPSS statistical package version 
22 (IBM, New York, NY, USA), SAS version 9.3 (SAS Institute Inc., Cary, NC, USA), 
Statexact v4 (Cytel Software Corporation, USA), R version 3.2.2 (The R foundation, Vienna, 
Austria) or with Medcalc version 14 (Medcalc Software, Ostend, Belgium). The Mann–
Whitney U test was used to evaluate continuous variables. For dichotomous variables, 
Fisher’s exact test was used to compare differences between groups. Cox proportional 
hazards regression analysis was used for uni- and multivariate time to event analyses for 
dichotomous endpoints (CCA or dysplasia/benign histology/follow-up). The penalized 
maximum likelihood (lasso) with standardized variables (the glmnet R-package; www.cran.r-
project.org) was also used. Inflammation in the BCs was calculated as inflammatory burden 
during the follow-up period, integrating the semi-quantitative neutrophil score (0-2) over time 
to obtain the area under the curve. The result was normalised using the follow-up period, 
resulting in an average weighted score for inflammation ranging from 0 to 2. A corresponding 
‘burden value’ was also calculated for aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), 
bilirubin, carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9) in 
addition to using the actual laboratory values. mERC score burden was also calculated from 
total, intrahepatic and extrahepatic mERC scores, correspondingly. For continuous 
variables, we used a logarithmic transformation if necessary. For comparison, a 
corresponding analysis was also performed using biliary neoplasia (CCA or dysplasia) or 
benign follow-up/histology as dichotomous endpoints (see Supplementary Table I). The first 
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ERC date in our unit in the period beginning in 2006 was defined as the beginning of the 
surveillance period. 
Ethics. The local ethics committee of Helsinki University Hospital for Internal Medicine, has 
approved the study protocol, number 278/13/03/01/2009.  
 
Results 
Endpoints. The median follow-up time was 6 years. In total, CCA was diagnosed in 17 (3.8%) 
patients, including two with liver transplantation. The median time to diagnosing CCA after 
PSC diagnosis stood at 3 years (IQR 0.25–12.9, range 0–19.5 years). Two patients were 
diagnosed with CCA in the initial ERC, and three were diagnosed with CCA within five 
months of the initial ERC. Ten CCAs were located in extrahepatic, hilar or perihilar bile ducts, 
and three were intrahepatic. In four cases, the origin of the tumour could not reliably be 
determined. More detailed information about CCA patients is presented in Supplementary 
Table II. A majority (424 or 94.9%) of patients presented with a non-malignant disease 
course, including biliary dysplasia in 23 (8 high-grade, 15 low-grade) explanted livers, benign 
biliary histology in 21 explanted livers and 383 patients with benign follow-up. LT was 
performed altogether for 46 (10.3%) patients. Three patients had hepatocellular carcinoma 
in the explanted liver, two of them having also low-grade dysplasia of the bile ducts. After 
median 4.2 years of liver transplantation, 20/23 patients with biliary dysplasia of the 
explanted liver were alive with no signs of biliary malignancy. One patient had been 
diagnosed with adenocarcinoma of the papilla Vater. One died of malignancy in pancreas, 
and one of metastatic hepatocellular carcinoma. Gallbladder carcinoma or carcinoma in situ 
was diagnosed in three patients. The outcome of the surveillance cohort is presented in 
Figure 2. 
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ERC scores. In the first ERC of this study period, we detected intrahepatic PSC alone in 256 
patients, and intra- and extrahepatic disease in 191 patients (Table I). All patients with CCA 
during follow-up had both intra- and extrahepatic ERC changes in their first ERC.  
Laboratory values. ALP measured at the beginning of surveillance was significantly higher 
among patients who developed CCA, as well as bilirubin, GGT, AST, ALT, CA19-9, and 
CEA (p=<0.001–0.021). Table II shows the laboratory values at the beginning of the 
surveillance according to the endpoint. CA19-9 was over the upper limit of normal (ULN) 
(>26 kU/L) at some point during surveillance among 54 patients (12.1%), 7 of whom were 
diagnosed with CCA and 5 with biliary dysplasia. CA19-9 was markedly elevated (>129 
kU/L) among 7 patients, 5 of whom had CCA and 2 had a benign follow-up (16). On the 
other hand, CA19-9 was at some point elevated during surveillance in 7/17 (41.2%) CCA 
patients and in 5/23 (21.7%) of the patients with biliary dysplasia.  
BCs and ploidy analysis. Among all 788 BCs, 713 (90.5%) were benign, 72 (9.1%) 
suspicious, and 3 (0.4%) were malignant. Ploidy analysis was performed in 486 ERCs 
(62%), out of which 28 (5.8%) were aneuploid (DNA index >1.1). BC was suspicious or 
malignant at least once in 12 (70.6%) out of 17 CCA patients (Table III). Among the 21 
explanted livers with benign biliary histology, 17 (81.0%) showed preoperative benign and 
diploid BCs. In total, 185 patients presented with an inflammatory burden >0.25 in BC, with 
most CCAs (16/17) detected among them. If the inflammatory burden was low at <0.25, only 
one CCA was detected among 262 patients. 
Sensitivity and specificity. If one suspicious or malignant BC was regarded as a positive 
cytology and if all BCs must be benign for a negative cytology, the sensitivity to detect CCA 
with BC reached 71%, with 91% specificity across the entire study population (Table III). 
There was a tendency toward better sensitivity in the surveillance cohort (100%). Combining 
DNA flow cytometry and BC, the sensitivity and specificity were not significantly higher. If 
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biliary neoplasia (CCA or dysplasia) was used as an endpoint, the sensitivity of BC was 65% 
with 94% specificity, not being significantly better combined with DNA flow cytometry. We 
found eight patients with DNA index of 1.50 or higher. Three of them were diagnosed with 
CCA and four had high-grade dysplasia.  
Risk factors. Patients with more advanced biliary disease (mERC score burden >8) exhibited 
a significantly elevated hazard ratio (HR) for CCA (p<0.001; Table IV). These results were 
similar for intrahepatic, extrahepatic and total mERC scores. Men exhibited a significantly 
higher HR for CCA compared with women (p=0.025). Other significant factors for CCA in 
the univariate analysis included the inflammation burden in BC, ALT burden, AST burden, 
ALP burden, GGT burden, bilirubin burden, CEA > ULN burden and CA19-9 > ULN burden 
(p<0.001). Furthermore, the burden of suspicious BCs or suspicious BC in the first ERC 
posed a significant risk factor, as well as aneuploidy at some point during the follow-up 
period (p<0.001-0.005). We did not analyse aneuploidy further, since we only had data on 
this variable for a portion of our patients. In multivariate analysis we found a suspicious BC 
burden over 0.05, CEA>ULN burden and GGT burden represented significant independent 
risk factors for CCA (p<0.001, p<0.001, and p=0.005, respectively). Corresponding analysis 
for neoplasia (dysplasia or CCA) can be found in Supplementary Table I.  
 
 
Discussion 
In this large single centre study including 447 non-selected PSC patients with 788 ERCs 
and BCs with a median follow-up of 6 years, CCA was detected in 17 (3.8%) patients, and 
a non-malignant course of disease, including biliary dysplasia (5.1%), was seen in 424 
patients. LT was performed in 46 patients. The sensitivity of suspicious/malignant BC was 
71 to 100% with specificity of 91 to 93% in detecting CCA. To our knowledge, this is the first 
study evaluating the role of regular surveillance among non-selected PSC patients with 
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ERC, using detailed ERC scoring, systematic BC, presence of inflammation in BC, and 
laboratory values in relation to the risk of CCA. 
Essential risk factors for CCA and dysplasia included advanced ERC changes, male gender, 
elevated ALT, AST, GGT, ALP, bilirubin, CA19-9 or CEA, suspicious BC, inflammation in 
BC, and male gender. The presence of IBD did not correlate with biliary neoplasia, which is 
in line with some previous results (17), but somewhat differs from a US-based study (18). 
CA 19-9 is often elevated with CCA, but in PSC, up to one-third of patients may have an 
elevated CA 19-9 in the absence of CCA (16,19).  The AASLD Guidelines for PSC (20) do 
not recommend screening for CCA based on cytology. Our protocol differs from these 
guidelines. Based on the present study, individual risk stratification and targeting screening 
for the patients with highest CCA risk could be possible, if early liver transplantation or other 
early treatment is an option. 
In an earlier study conducted in our hospital (9), ploidy analysis increased the sensitivity in 
the detection of biliary neoplasia. The material in the previous study, however, consisted of 
selected patients with a more advanced stage of PSC. This study then challenges the 
additional benefit of ploidy analysis among non-selected PSC patients due to the solid 
sensitivity of BC alone. The lack of additional advantage of ploidy analysis was also seen in 
another study among patients with newly diagnosed PSC (15). Also, the BC samples at the 
present study with the new collection technique were more representative containing an 
abundance of cells. 
Inflammation in BC turned out to be a significant risk factor for CCA in this study. 
Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 expression in non-
neoplastic and CCA tissue is also up-regulated in PSC patients, emphasising the importance 
of inflammation in the carcinogenesis of PSC patients (21). Neutrophilic inflammation is 
easily graded in BC, and, according to our study, stands as a significant co-factor with ERC 
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changes for biliary neoplasia. We used inflammation burden in BCs in statistical analysis to 
evaluate the effect of continuous inflammation as a risk factor for CCA or dysplasia. It is, 
however, to be noted that inflammation in BC was common, and only 7.5% (11/146) of 
patients having purulent inflammation in the first ERC of the study period were later 
diagnosed with CCA.  On the other hand, CCA was only seen in one patient with no 
inflammation burden in BC, patient having only one BC available during the study period. 
Inflammation in the colon biopsies of IBD patients predicts the risk of colorectal carcinoma 
and the use of immune modulators seems to reduce the risk (22,23). The same is most likely 
to be true also with PSC. Using a combination of UDCA and metronidazole to reduce the 
inflammation of the bile ducts is reflected by decrease of ALP levels (24). The use of UDCA 
was not possible to include into statistical analysis, since 93% of patients were on UDCA 
therapy and it was not randomised.  
Our aim was to determine the risk factors for CCA to target the surveillance of PSC patients 
better. The question remains, if prevention of CCA with liver transplantation is possible with 
systematic surveillance using ERC with BC. Low-grade dysplasia is a strong predictor of 
high-grade dysplasia in the bile ducts (6), but the natural course of dysplasia is not well 
characterized. Cytogenetic abnormalities similar to CCA are detected in low-grade dysplasia 
although less commonly than in high-grade dysplasia (25). Since CCA is generally regarded 
as a contraindication for LT, we were probably able to prevent several CCAs in this group 
of patients through systematic screening and early referral for liver transplantation. However, 
not all liver transplantations were performed due to neoplasia suspicion, but due to end-
stage liver disease or clinical symptoms. Still, 12 patients developed CCA more than one 
year after their PSC diagnosis, seven (58.3%) of them presenting with suspicious/malignant 
BC.  
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BC interpretation is always subjective due to lack of objective markers. The number of BCs 
and the time between BCs varied considerably between patients, which might represent a 
weakness of this study. This was, however, taken into consideration in our statistical 
analysis.  
Although ERC is an invasive method, our complication rate is acceptably low. In an earlier 
study from our unit, including 441 ERCs of PSC patients during 2007-2009, post-ERC 
pancreatitis was seen in 31 patients (7.0%), of which three severe cases. All were treated 
conservatively (26). Cholangitis after ERC was seen 6 patients (1.4%). This is comparable 
to previous studies (27). Considering the high risk of CCA in PSC patients, and the fact that 
PSC patients are often young, we find this complication rate acceptable. In patients with 
advanced age or other serious illnesses, ERC surveillance is not indicated,if the patients are 
not candidates for liver transplantation due to concomitant diseases. On the other hand, 
ERC with dilatation and stent placement if needed for dominant strictures in PSC is 
recommended in order to increase patients’ survival (28). Dilatation and stenting is widely 
used for this purpose in our unit, and BC is regularly taken subsequently with dilatation to 
find a possible malignancy associated with strictures. Dominant stricture in our scoring 
equals to mERC score ≥3 for extrahepatic bile ducts. However, not all CCAs can be 
prevented by ERC surveillance and liver transplantation. In ulcerative colitis, endoscopic 
surveillance is routinely performed because of the elevated colorectal cancer risk of 2.4-fold 
(29), whereas the risk of CCA in PSC patients is much more significantly increased, with the 
lifetime risk reaching almost 10% (1), or 398-fold compared to that for general population 
(2). Still, most centres carry no systematic surveillance for biliary dysplasia. It is debatable 
if the risk of complications of ERC and liver transplantation are acceptable. Only patients 
with repeatedly suspicious BC and the highest risk for CCA are considered for early liver 
transplantation. In addition, ERCs for PSC patients are performed by very experienced 
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gastroenterologists to minimize the risks of the procedure, and to obtain representative BCs 
in our unit. 
In conclusion, in this large study of non-selected PSC patients, advanced ERC changes with 
neutrophilic inflammation in BC along with suspicious BC, male gender, elevated AST, ALT, 
ALP, bilirubin, GGT, CA19-9, and CEA indicated a higher risk of CCA and dysplasia. ERC 
surveillance with BC might be most beneficial for patients with such findings and could 
possibly identify patients with risk of progression to CCA if early LT is possible. 
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Table I. Demographics.  
Demographic characteristics of the whole study population in the beginning of 
surveillance according to the endpoint. 
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 Range Benign/dysplasia  
(96,2%)** 
CCA  
(3.8%) 
P 
Patients, n (M/F) . 430 (234/196) 17 (13/4) 0.085 
Age at PSC diagnosis, years  10-69 36 (27-48)  43 (31-57) 0.164 
Symptomatic (%) . 17% 47% 0.005  
ERC findings      
-Intrahepatic only, n (%)  256 (60%) 0 (0%) <0.001 
-Intra+extrahepatic, n (%)  174 (40%) 17 (100%) <0.001 
-Intrahepatic mERC-score  (IQR) 2-8 4 (2-6) 6 (6-6) <0.001 
-Extrahepatic mERC-score (IQR) 0-7 0 (0-2) 3 (2-5.5) <0.001  
-Total mERC-score (IQR) 2-14 4 (2-8) 9 (8-11) <0.001 
Liver transplantation*, n . 44 2 0.691  
IBD, n (%)* . 316 (73%) 16 (94%) 0.085  
UC/CD/Indeterminate, n . 230/70/16 14/1/1  0.338 
IBD duration, years (IQR) 0-44 6.0 (1.3-13.1) 15.0 (4.6-21.0) 0.103 
IBD after PSC diagnosis, n . 18 3 0.040  
Intestinal dysplasia*, n . 41 0 0.472  
CRC*, n . 8 0 1.000  
Colectomy*, n . 55 4 0.039 
AIH, n . 38 1 1.000  
UDCA*, n . 404 10 <0.001  
Metronidazole*, n . 113 3 0.577  
Abbreviations: AIH, autoimmune hepatitis; CCA, cholangiocarcinoma; CD, Crohn's disease; CRC, colorectal carcinoma; F, female; 
IBD, inflammatory bowel disease; Indeterminate, indeterminate colitis; IQR, interquartile range; M, male; mERC score, modified 
Amsterdam ERC score; UC, ulcerative colitis; UDCA, ursodeoxycholic acid 
*at the end of surveillance 
**including 3 patients with gallbladder carcinoma or carcinoma in situ and 3 patients with hepatocellular carcinoma 
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p values calculated with Mann-Whitney U test for dichotomous variables, and with Fisher’s exact test for continuous variables. 
Continuous results are show as median (IQR). 
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Table II. Laboratory values.  
Laboratory values at the beginning of systematic surveillance.  
  
    
 
 Range Benign/dysplasia  
(96,2%)* 
CCA  
(3.8%) 
P 
Hb, g/L (IQR) 93-174 139 (127-148) 128 (115-149)  0.198 
Platelets, x 109 (IQR) 49-736 249 (207-298) 269 (216-329) 0.293  
Albumin, g/L (IQR) 23.8-78.0 38.6 (35.7-40.9) 39.7 (36.8-40.3) 0.944  
TT, % (IQR) 19-170 108 (92-124) 107 (85-132)  0.675 
INR (IQR) 0.8-2.4 1.0 (0.9-1.1) 1.1 (0.9-1.1) 0.243  
Bilirubin, µmol/L (IQR) 2-426 11 (8-17) 29 (13-117) <0.001  
ALP, U/L (IQR) 12-1002 116 (85-181) 244 (154-385) <0.001  
GGT, U/L (IQR) 10-1979 76 (28-215) 237 (119-643) 0.002  
AST, U/L (IQR) 13-276 34 (25-51) 50 (36-94) 0.002  
ALT, U/L (IQR) 4-537 37 (22-69) 55 (40-134) 0.021 
CA19-9, kU/L (IQR) 2-1035 5 (3-11) 14 (6-73) 0.009  
CEA, µg/L (IQR) 1-28 1.4 (1.0-2.3) 2.8 (1.2-10.1) 0.014  
IgG4, g/L (IQR) 0.01-5.54 0.47 (0.22-0.94) 0.98 (0.45-1.18) 0.159  
CRP, mg/L (IQR) 0-107 3 (3-5) 3 (3-11) 0.806 
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Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CA19-9, carbohydrate 
antigen 19-9; CEA, carcinoembryonic antigen, CRP, C-reactive protein; GGT, gamma-glutamyl transferase; Hb, haemoglobin;  IgG4, 
immunoglobulin G4; INR, international normalized ratio; TT, thromboplastin time 
*including 3 patients with gallbladder carcinoma or carcinoma in situ and 3 patients with hepatocellular carcinoma 
p-values calculated with the Mann-Whitney U test. Results are shown as median (IQR). 
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Table III. Sensitivity and specificity. 
Sensitivity and specificity of BC and DNA flow cytometry in the detection of CCA or biliary 
neoplasia (CCA or dysplasia). 
ALL PATIENTS Histology or follow-up (n)  95% CI 
   Sens: 71% 44.04-89.69% 
BC only (n=447) CCA Benign/Dysplasia Spec: 91% 87.81-93.47% 
BC suspicious/malignant 12 39 PPV: 24% 12.79-37.49% 
BC benign 5 391 NPV: 98% 97.08-99.59% 
     
   Sens: 71% 44.04-89.69% 
BC or FC (n=250) CCA Benign/dysplasia Spec: 81% 75.49-85.93% 
Suspicious or aneuploid 12 44 PPV: 21% 11.59-34.44% 
Benign and diploid 5 189 NPV: 97% 94.09-99.16% 
     
SURVEILLANCE COHORT   
   Sens: 100% 63.06-100.0% 
BC only (n=262) CCA Benign/dysplasia Spec: 93% 88.56-95.44% 
BC suspicious/malignant 8 19 PPV: 30% 13.75-50.18% 
BC benign 0 235 NPV: 100% 98.44-100.0% 
   Sens: 100% 63.06-100.0% 
BC or FC (n=107) CCA Benign/dysplasia Spec: 79% 69.42-86.36% 
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Suspicious or aneuploid 8 21 PPV: 28% 12.73-47.24% 
Benign and diploid 0 78 NPV: 100% 95.38-100.0% 
ENDPOINT  NEOPLASIA (CCA or biliary dysplasia, all patients)  
   Sens: 65% 48.32-79.37% 
BC only (n=447) Neoplasia Benign Spec: 94% 91.07-95.99% 
BC suspicious 26 25 PPV: 51% 36.60-65.25% 
BC benign 14 382 NPV: 96% 94.14-98.05% 
     
   Sens: 69% 52.43-82.98% 
BC or FC (n=250) Neoplasia Benign Spec: 86% 80.86-90.60% 
Suspicious or aneuploid 27 29 PPV: 48% 34.66-61.97% 
Benign and diploid 12 182 NPV: 94% 89.44-96.76% 
     
  
Abbreviations: BC, brush cytology; CCA, cholangiocarcinoma; CI, confidence interval; FC, DNA 
flow cytometry; NPV, negative predictive value; PPV, positive predictive value; Sens, sensitivity; 
Spec, specificity 
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Table IV. Risk factors. 
Univariate and multivariate analyses of risk factors for CCA. 
 
     
Univariate 
 
95% CI 
 
Variable HR lower upper P 
Age at beginning of follow-up (years) 1.0 1.0 1.1 0.329 
Sex (male/female) 5.5 1.2 24.3 0.025 
Inflammation burden in BC  3.9 2.0 7.8 <0.001 
Extrahepatic mERC score burden 1.5 1.2 1.9 <0.001 
Intrahepatic mERC score burden 2.0 1.4 2.9 <0.001 
Total mERC score burden 1.4 1.2 1.6 <0.001 
mERC score burden >4 54.9 0.8 3592.3 0.061 
mERC score burden >8 18.8 4.2 83.5 <0.001 
ALT burden 9.5 2.5 36.6 <0.001 
AST burden 24.3 5.3 111.3 <0.001 
GGT burden 10.9 4.1 29.0 <0.001 
Bil burden 43.3 15.5 120.9 <0.001 
Bil >ULN burden 13.0 4.1 40.7 <0.001 
ALP burden 27.3 5.3 139.9 <0.001 
CEA > ULN burden 15.4 4.8 49.1 <0.001 
CA19-9 > ULN burden 9.8 3.5 28.1 <0.001 
Time from diagnosis to start of follow-up 1.5 0.8 2.7 0.197 
Suspicious BC at first ERC 13.9 5.0 38.4 <0.001 
Suspicious BC burden 31.6 11.0 90.9 <0.001 
Suspicious BC burden >0.05 18.1 6.4 51.4 <0.001 
Aneuploidy some time during follow-up 5.2 1.6 16.3 0.005 
Multivariate     
GGT burden 9.3 (1.8) 1.9 44.0 0.005 
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Bil > ULN burden 3.1 (2.0) 0.8 12.3 0.101 
CEA > ULN burden 22.1 (6.3) 5.2 93.2 <0.001 
Suspicious BC burden >0.05 18.8 (6.0) 5.1 68.5 <0.001 
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; BC, brush cytology; Bil, bilirubin; CA19-9, carbohydrate antigen 19-9; CEA, 
carcinoembryonic antigen; GGT, gamma-glutamyl transferase; mERC score, modified Amsterdam 
ERC score; ULN, upper limit of normal value 
Logarithmic transformation was used in continuous ALP, AST, ALT, GGT, CA 19-9, and CEA 
variables. The following variables were used for parameter selection into the multivariate model: sex, 
age, mERC score (total), suspicious/malignant brush cytology>0.05, ALP>ULN, ALT, GGT, CA19-
9>ULN, CEA>ULN, bilirubin>ULN, Inflammation burden in BC>0.65 and time from diagnosis to start 
of follow-up. Nonzero HRs from the penalized (lasso) Cox model are shown in parentheses; other 
values are from unpenalized Cox models fitted with the parameters stated in the table. 
 
 
 
 
 
 
 
 
 
FIGURE LEGENDS 
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Figure 1. Surveillance protocol for PSC patients at Helsinki University Hospital. 
Abbreviations: AMA, antimitochondrial antibody; CT, computed tomography; IBD, 
inflammatory bowel disease; mERC score, modified Amsterdam ERC score; MRI, magnetic 
resonance imaging; US, ultrasound 
Figure 2. Outcome of the patients in the surveillance cohort. Abbreviations: BC, brush 
cytology; CCA, cholangiocarcinoma 
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